Chordia Therapeutics Inc. ( (JP:190A) ) just unveiled an announcement.
Chordia Therapeutics Inc. has announced that Ono Pharmaceutical Co., Ltd. will discontinue the development of CTX-177 (ONO-7018) for strategic reasons, returning all rights to Chordia. While this decision ends the potential for milestone payments from Ono, Chordia does not foresee an immediate impact on its current R&D activities, including ongoing studies of its lead pipeline asset, rogocekib. The company will explore future business options for CTX-177 and manage the transition of ongoing studies and data.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a pharmaceutical company engaged in the development of innovative cancer therapies. Its lead asset, rogocekib, is in Phase 1/2 clinical trials in the US, targeting cancer vulnerabilities. The company also researches other clinical and preclinical assets, including MALT1 inhibitor CTX-177, CDK12 inhibitor CTX-439, and GCN2 inhibitors.
YTD Price Performance: -24.37%
Average Trading Volume: 911,830
Technical Sentiment Signal: Strong Buy
Find detailed analytics on 190A stock on TipRanks’ Stock Analysis page.